MarketPulse

Phase 3 study

5 articles
BenzingaBenzinga··Vandana Singh

BioMarin's Dwarfism Treatment Hits Milestone, Stock Jumps on Phase 3 Success

BioMarin's VOXZOGO met primary endpoint in hypochondroplasia study, showing significant growth improvement. Stock surged 8% on positive data.
BMRNFDA approvalPhase 3 study
GlobeNewswire Inc.GlobeNewswire Inc.··Na

aTyr Pharma Advances Sarcoidosis Drug After FDA Meeting, Extends Cash Runway

aTyr Pharma advances efzofitimod into Phase 3 pulmonary sarcoidosis development following FDA meeting, maintains $68.3M cash position.
ATYRclinical developmentinterstitial lung disease
GlobeNewswire Inc.GlobeNewswire Inc.··The Portnoy Law Firm

Rezolute Stock Plunges 87% After Failed Drug Trial, Securities Probe Launched

Rezolute's lead drug candidate failed Phase 3 trials, triggering massive stock collapse and securities fraud investigation by Portnoy Law Firm.
RZLTsecurities fraud investigationstock price collapse
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Urges $GOSS Investors to Act Before Deadline in Securities Fraud Suit

Rosen Law Firm filed class action against Gossamer Bio alleging false statements about Phase 3 PROSERA study design. Eligible investors must act before deadline.
PFSIGOSSZSPCsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Mereo BioPharma Stock Collapses 88% on Failed Trials; Class Action Lawsuit Filed

Pomerantz Law Firm files securities fraud lawsuit against $MREO after failed Phase 3 trials tank stock 87.7%. Lead Plaintiff deadline: April 6, 2026.
MREORAREsecurities fraudclass action lawsuit